Research To Practice | Oncology Videos

Research To Practice

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

  1. 5 DAYS AGO · VIDEO

    Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

    Featuring an interview with Dr Kevin Kalinsky, including the following topics: Patient-Reported Outcomes from the TROPION-Breast01 Study (0:00) Pernas S et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes from the TROPION-Breast01 study. ASCO 2024;Abstract 1006. Indirect Comparison of Sacituzumab Govitecan and Datopotamab Deruxtecan for Advanced Breast Cancer (5:04) Pathak N et al. Indirect comparison of sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) in advanced breast cancer (aBC): Safety and efficacy analysis. San Antonio Breast Cancer Symposium 2024;Abstract P1-02-02. BEGONIA: A Phase Ib/II Study of Datopotamab Deruxtecan with Durvalumab as First-Line Treatment for Unresectable Advanced Triple-Negative Breast Cancer (9:53) Schmid P et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study. ESMO 2023;Abstract 379MO. Advances in the Use of TROP2-Targeted Antibody-Drug Conjugates for Breast Cancer: Mechanisms, Clinical Applications and Future Directions (15:35) Tong Y et al. Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: Mechanisms, clinical applications, and future directions. Front Immunol 2024;15:1495675. Abstract CME information and select publications

    22 min

  2. 23 SEPT · VIDEO

    Metastatic BRCA-Negative Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management

    Featuring an interview with Prof Peter Schmid, including the following topics: Response to immunotherapy in breast cancer subtypes (0:00) Tolerability of TROP2 antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC) (3:51) Approaches to therapy for patients with HR-negative HER2-low and HER2-ultralow mBC (13:03) ADC structure and treatment-related adverse events (19:02) Available data from the Phase III ASCENT-04 trial evaluating sacituzumab govitecan with pembrolizumab as first-line therapy for patients with PD-L1-positive advanced triple-negative breast cancer (23:06) Novel ADCs and bispecific antibodies under investigation for mBC (28:30) Comparing datopotamab deruxtecan and sacituzumab govitecan for HR-positive disease (33:01) Clinical investigator perspectives on the Phase III DESTINY-Breast09 trial evaluating first-line trastuzumab deruxtecan with or without pertuzumab versus THP (docetaxel/rastuzumab/pertuzumab) for HER2-positive mBC (35:06) CME information and select publications

    41 min

  3. 22 SEPT · VIDEO

    Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management (Companion Faculty Lecture)

    Featuring a slide presentation and related discussion from Prof Peter Schmid, including the following topics: Evolution of the therapeutic landscape for metastatic triple-negative breast cancer; age of immunotherapy (0:00) Case: A woman in her early 40s with no actionable mutations (7:29) Evolution of antibody-drug conjugates (ADCs) in the management of metastatic breast cancer (11:13) TROP2-directed ADCs (15:22) Case: A woman in her early 50s with PD-L1-negative, HR-negative, HER2-low de novo metastatic breast cancer (20:21) Novel strategies utilizing approved and investigational ADCs (23:28) Case: A woman in her early 60s with loss of HER2 expression on disease progression (31:39) ADCs in combination with immunotherapy (32:51) CME information and select publications

    40 min

  4. 21 SEPT · VIDEO

    Extrapulmonary Neuroendocrine Carcinoma — An Interview with Dr Jonathan Strosberg on Current and Future Management

    Featuring an interview with Dr Jonathan Strosberg, including the following topics: Overview of extrapulmonary neuroendocrine carcinoma (NEC) (0:00) Treatment strategies for extrapulmonary NEC (10:26) Targeting DLL3 in extrapulmonary NEC (18:49) Early clinical data with obrixtamig for extrapulmonary NEC (21:56) Additional investigational agents for extrapulmonary NEC (25:44) Case: A woman in her mid 50s with poorly differentiated metastatic NEC of unknown primary (27:20) Case: A man in his early 60s with poorly differentiated metastatic esophageal NEC (32:30) Clinical management of well-differentiated NEC (36:58) CME information and select publications

    45 min

  5. 20 SEPT · VIDEO

    Oncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell Therapy

    Featuring an interview with Dr Beth Faiman, including the following topics: Clinical practice background and historical view of treatment for multiple myeloma (MM) (0:00) Fundamental principles associated with chimeric antigen receptor (CAR) T-cell therapy (7:19) Sequencing of CAR T-cell therapy and bispecific antibodies in the MM treatment landscape (9:00) Patient eligibility to receive CAR T-cell therapy (13:23) Differentiating among approved CAR T-cell therapies for MM (18:18) Durability of responses to CAR T-cell therapy for MM (24:01) Neurotoxicity with CAR T-cell therapies for MM (26:26) Minimal residual disease monitoring in MM (29:39) Support systems for the management of toxicities associated with CAR T-cell therapy (35:10) Patients with MM experiencing durable responses to CAR T-cell therapy (43:11) NCPD information and select publications

    53 min

  6. 19 SEPT · VIDEO

    Extrapulmonary Neuroendocrine Carcinoma — An Interview with Dr Jonathan Strosberg on Current and Future Management (Companion Faculty Lecture)

    Featuring a slide presentation and related discussion from Dr Jonathan Strosberg, including the following topics: Overview of the classification, grading and incidence of neuroendocrine carcinoma (NEC) (0:00) Overview of mutational profile, biomarker assessments and prognosis of NEC (3:45) Current treatment paradigm for extrapulmonary NEC (8:59) DLL3 as an emerging target biomarker in extrapulmonary NEC (17:46) Novel therapeutic agents under investigation for extrapulmonary NEC (23:05) CME information and select publications

    26 min

  7. 17 SEPT · VIDEO

    Metastatic Triple-Negative Breast Cancer — The Selection and Sequencing of Therapy

    Featuring perspectives from Dr Ana C Garrido-Castro and Prof Peter Schmid, including the following topics:  Introduction: Legendary Figures in Breast Cancer Research (0:00) Case: A woman in her early 80s, a current smoker with a history of myocardial infarction and stroke, who develops recurrent triple-negative breast cancer (TNBC) — Justin Favaro, MD, PhD (6:44) Case: A woman in her late 60s with metastatic TNBC and a PD-L1 level of 20% who receives chemotherapy/pembrolizumab followed by sacituzumab govitecan — Priya Rudolph, MD, PhD (25:08) Case: A woman in her late 60s with localized TNBC who develops myocarditis while receiving neoadjuvant chemotherapy/pembrolizumab — Richard Zelkowitz, MD (33:53) Case: A woman in her mid 60s with recurrent ER-negative, HER2-low, PI3K-mutant TNBC — Ranju Gupta, MD (37:49) Case: A woman in her early 60s with recurrent TNBC confined to contralateral neck nodes — Eric H Lee, MD, PhD (42:10) Case: A woman in her early 40s with metastatic TNBC who receives sacituzumab govitecan after multiple lines of chemotherapy — Estelamari Rodriguez, MD, MPH (48:10) Case: A woman in her mid 70s with ER-negative, HER2-low breast cancer who develops an isolated brain metastasis — Dr Gupta (55:02) CME information and select publications

    59 min

  8. 16 SEPT · VIDEO

    Ocular Toxicities Associated with ADCs and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management

    Featuring an interview with Dr Neel Pasricha, including the following topics: Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00) Association of corneal toxicities with ADCs (4:56) Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02) Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44) Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55) Other ocular toxicities associated with cancer therapies (24:26) Prevention and management of corneal toxicity (33:58) Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39) General clinical pearls on the management of ocular toxicities with cancer therapies (48:04) CME information and select publications

    54 min
See All (300)

About

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Information

More From Research To Practice

You Might Also Like